Брой 1/2024, Статии

Приложение на Ритуксимаб при кортико – зависим и често рецидивиращ нефротичен синдром в детската възраст

Публикувана на от admin

Г. Златанова

Клиника по детска нефрология и хемодиализа, СБАЛДБ „Проф. Иван Митев“ – София,
Катедра по Педиатрия, МУ- София

Резюме

Нефротичният синдром в детската възраст най- често протича като кортико – чувствителен, но около 50 – 60 % от пациентите са с чести рецидиви (ЧРНС) или проявяват кортико – зависимост (КЗНС). От много години кортикостероидите (КС) стоят в основата на лечението на заболяването. Продължителният им прием излага много деца с КЗ/ЧРНС на риск от стероидна токсичност. С цел освобождаване от КС терапия и поддържане на ремисия се използват различни имуносупресори, като напр. ритуксимаб. Медикаментът представлява моноклонално антитяло срещу CD20 рецептора на В- лимфоцитите и показва обещаващи резултати при лечението на НС в детската възраст. Целта на настоящия обзор е да представи в обобщен вид наличната към момента информация относно приложението на ритуксимаб при деца с ЧР/КЗНС. Извършен е преглед на достъпната медицинска литература за последните двайсетина години.

Ключови думи: кортико – зависим нефротичен синдром, често рецидивиращ нефротичен синдром, ритуксимаб, детска възраст

To access this content, you must purchase Годишен абонамент.

Библиография

  1. Mc Kinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatric nephrology. 2001;16(12):1040-4
  2. Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61–74
  3. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic signifcance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776
  4. Carter SA, Mistry S, Fitzpatrick J, Banh T, Hebert D, Langlois V, Pearl RJ, Chanchlani R, Licht CPB, Radhakrishnan S, Brooke J, Reddon M, Levin L, Aitken-Menezes K, Noone D, Parekh RS (2020) Prediction of short- and long-term outcomes in childhood nephrotic syndrome. Kidney Int Rep 5:426–434
  5. Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN) (1982) Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 306:451–454
  6. Trautmann, A., Boyer, O., Hodson, E. et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38, 877–919 (2023) https://doi.org/10.1007/s00467-022-05739-3
  7. Hahn D SS, Willis NS, Craig JC, Hodson EM (2020) Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2020(8):CD001533
  8. Azib S, Macher MA, Kwon T, Dechartres A, Alberti C, Loirat C, Deschênes G, Baudouin V. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011 Jun;26(6):927-32. doi: 10.1007/s00467-011-1830-0. Epub 2011 Mar 12. PMID: 21394465
  9. Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschênes G, Jacqz-Aigrain E, Loirat C. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol. 2012 Mar;27(3):389-96. doi: 10.1007/s00467-011-2006-7. Epub 2011 Sep 28. PMID: 21947272
  10. Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol. 2008 Nov;23(11):2013-20. doi: 10.1007/s00467-008-0899-6. Epub 2008 Jul 12
  11. Gellermann J, Weber L, Pape L et al. Gesellschaft für Pädiatrische Nephrologie (GPN).Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.J Am SocNephrol. 2013 Oct;24(10):1689-97. doi: 10.1681/ASN.2012121200. Epub 2013 Jun 27
  12. Hogg RJ, Fitzgibbons L, Bruick J, et al. Mycophenolate mofetil in children withfrequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1:1173–8
  13. Anne K. Mühlig,Jun Young Lee, Markus J. Kemper, et al. Levamisole in Children with Idiopathic Nephrotic Syndrome: Clinical Efficacy and Pathophysiological AspectsJ Clin Med. 2019 Jun; 8(6): 860.Published online 2019 Jun 16. doi: 10.3390/jcm8060860
  14. Kuźma-Mroczkowska E, Skrzypczyk P, Pańczyk-Tomaszewska M Epub 2016 Oct 25.Levamisole therapy in children with frequently relapsing and steroid-dependent nephrotic syndrome: a single-center experience. Cent Eur J Immunol.  2016;41(3):243-247
  15. Gruppen MP, Bouts AH, Jansen-van der Weide MC, et al. A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome. Kidney Int. 2018 Feb;93(2):510-518. doi: 10.1016/j.kint.2017.08.011. Epub 2017 Oct 18
  16. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14:931–8
  17. Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol. 2013;24:1689–97
  18. Ishikura K, Yoshikawa N, Nakazato H, et al. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin J Am Soc Nephrol. 2012;7:1576–83
  19. Hulton SA, Neuhaus TJ, Dillon MJ et al. Longterm cyclosporin A treatment of minimal-change nephrotic syndrome of childhood. Pediatr Nephrol. 1994;8:401–3
  20. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS.J Am Soc Nephrol. (2012) 23:2051–9. doi: 10.1681/ASN.2012030302
  21. Colucci M, Corpetti G, Emma F, Vivarelli M (2018) Immunology of idiopathic nephrotic syndrome. Pediatr Nephrol Berl Ger 33:573– 584
  22. Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthr Rheumat. (2013) 65:2783– 90. doi: 10.1002/art.38107
  23. Piantoni S, Scarsi M, Tincani A, Airo P. Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. Rheumatol Int. (2015) 35:1571–3. doi: 10.1007/s00296-015-3295-0
  24. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, AguillonPrada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. (2011) 3:85ra46. doi: 10.1126/scitranslmed.3002231
  25. Takahashi Y, Ikezumi Y, Saitoh A. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes. Nephrology. (2017) 22:49–57. doi: 10.1111/nep.12737
  26. Perosa F, Favoino E, Caragnano MA, Dammacco F (2006) Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107:1070–1077
  27. Chugh SS, Macé C, Clement LC, Avila MdelN, Marshall CB. (2014). Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease, Front Pharmacol. 5:23
  28. Counsilman CE, Jol-van der Zijde CM, Stevens J, Cransberg K, Bredius RG, Sukhai RN. Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol. (2015) 30:1367– 70. doi: 10.1007/s00467-015-3120-8
  29. Jacobs R, Langer-Jacobus T, Duong M, Stahl K, Haller H, Schmidt RE, et al. Detection and quantification of rituximab in the human urine. J Immunol Methods. (2017) 451:118–21. doi: 10.1016/j.jim.2017.09.001
  30. Stahl K, Duong M, Schwarz A, Wagner AD, Haller H, Schiffer M. Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol. (2017) 2017:1372859.doi: 10.1155/2017/1372859
  31. Maxted AP, Dalrymple RA, Chisholm D, McColl J, Tse Y, Christian MT, et al. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatric Nephrol. (2018) 34:855–63. doi: 10.1007/s00467-018-4172-3
  32. Delbet JD, Leclerc G, Ulinski T. Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery?, Pediatr Nephrol. (2018) 34:529–32. doi: 10.1007/s00467-018-4139-4
  33. Hahn D, Koh Y, Farquhar J. Efficacy of two versus four doses of rituximab for childhood nephrotic syndrome. Nephrol Dial Transpl. (2018) 33 (suppl_1):i306. doi: 10.1093/ndt/gfy104.FP773
  34. Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, et al. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatric Nephrol. (2019) 34:87–96. doi: 10.1007/ s00467-018-4063-7
  35. Chaudhuri A, Kambham N, Sutherland S, Grimm P, Alexander S, Concepcion W, et al. Rituximab treatment for recurrence of nephrotic syndrome in a pediatric patient after renal transplantation for congenital nephrotic syndrome of Finnish type. Pediatr Transpl. (2012) 16:E1837. doi: 10.1111/j.1399-3046.2011.01519.x
  36. Horinouchi T, Sako M, Nakanishi K, Ishikura K, Ito S, Nakamura H, et al. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequentlyrelapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). BMC Nephrol. (2018) 19:302. doi: 10.1186/s12882-018-1099-7
  37. Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K; Japanese Study Group of Kidney Disease in Children. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome. J Am Soc Nephrol. 2022 Feb;33(2):401-419. doi: 10.1681/ASN.2021050643. Epub 2021 Dec 8. Erratum in: J Am Soc Nephrol. 2022 May;33(5):1050. PMID: 34880074; PMCID: PMC8819987
  38. Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, et al. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatric Nephrol. (2019) 34:253–9. doi: 10.1007/s00467-018-4052-x
  39. Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y, Sakuraya K. Longterm outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome. Pediatric Nephrol. (2019) 34:353–7. doi: 10.1007/s00467-018-4145-6
  40. Kim JH, Park E, Hyun HS, Cho MH, Ahn YH, Choi HJ, et al. Long-term repeated rituximab treatment for childhood steroiddependent nephrotic syndrome. Kid Res Clin Prac. (2017) 36:257–263. doi: 10.23876/j.krcp.2017.36.3.257 
  41. Cortazar FB, Muhsin SA, Pendergraft WF IIIrd, Wallace ZS, Dunbar C, Laliberte K, et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep. (2018) 3:394–402. doi: 10.1016/j.ekir.2017.11.004
  42. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guerin V, Lapillonne H, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood–follow-up after CD19 recovery. Nephrol. Dial Transpl. (2012) 27:1083–9. doi: 10.1093/ndt/gfr405
  43. Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, et al. NEPHRUTIX: a randomized, double-blind, placebo vs Rituximabcontrolled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun. (2018) 88:91–102. doi: 10.1016/j.jaut.2017.10.006
  44. Iwabuchi Y, Miyabe Y, Makabe S, Nakano M, Manabe S, Karasawa K, et al. Comparison of the response of frequently relapsing steroiddependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease. Medicine. (2018) 97:42. doi: 10.1097/MD.0000000000012704
  45. Bonanni A, Calatroni M, D’Alessandro M, Signa S, Bertelli E, Cioni M, et al. Adverse events linked with the use of chimeric and humanized antiCD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol. (2018) 84:1238–49. doi: 10.1111/bcp.13548
  46. Kamei K, Ogura M, Sato M, Ito S, Ishikura K. Infusion reactions associated with rituximab treatment for childhoodonset complicated nephrotic syndrome. Pediatr Nephrol. (2018) 33:1013–8. doi: 10.1007/s00467-018-3900-z 
  47. Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, et al. Rituximab in refractory nephrotic syndrome. Pediatric Nephrol. (2010) 25:461–8, doi: 10.1007/s00467-009-1376-6
  48. Bonanni A, Calatroni M, D’Alessandro M, Signa S, Bertelli E, Cioni M, et al. Adverse events linked with the use of chimeric and humanized antiCD20 antibodies in children with idiopathic nephrotic syndrome. Br J Clin Pharmacol. (2018) 84:1238–49. doi: 10.1111/bcp.13548
  49. Spatafora M, Bellini T, Giordano C, Ghiggeri GM. A mild form of rituximabassociated lung injury in two adolescents treated for nephrotic syndrome. BMJ case Rep. (2015) 2015. doi: 10.1136/bcr-2015-212694
  50. Grenda R, Jarmuzek W, Rubik J, Migdał M, Pronicki M. Fatal rituximabassociated lung injury syndrome in a patient treated with rituximab for recurrence of post-transplant nephrotic syndrome. Pediatr Transplant. (2015) 19:E115–20. doi: 10.1111/petr.12481
  51. Maeda R, Kawasaki Y, Ohara S, Suyama K, Hosoya M. Serum sickness with refractory nephrotic syndrome following treatment with rituximab. CEN Case Rep. (2018) 7:69–72. doi: 10.1007/s13730-017-0297-7
  52. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med. (2003) 348:2691–4. doi: 10.1056/NEJM200306263482620
  53. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine. (2010) 89:308–18. doi: 10.1097/MD.0b013e3181f2caef
  54. Morita K, Shibano T, Maekawa K, Hattori M, Hida N, Nakamura S, et al. Crohn’s disease following rituximab treatment in a patient with refractory nephrotic syndrome. CEN Case Rep. (2019) 8:55–60. doi: 10.1007/s13730-018-0364-8
  55. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. (2010) 126:e243–6. doi: 10.1542/peds.2009-3395
  56. Galassi G, Testa F, Bianchi F, Cappelli G, Chiari A. Acute demyelinating neuropathy associated with rituximab treatment in a patient with relapsing nephrotic syndrome. CEN Case Rep. (2017) 6:215–6. doi: 10.1007/s13730-017-0264-3
  57. Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, et al. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol. (2013) 28:145–9. doi: 10.1007/s00467-012-2286-6
  58. Czarniak P, Załuska-Le´sniewska I, Zagozdzon I, Zurowska A. Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent nephrotic syndrome. Pediatr Nephrol. (2013) 28:987–8. doi: 10.1007/s00467-013-2457-0
  59. Sellier-Leclerc AL, Belli E, Guérin V, Dorfmüller P, Deschênes G. inant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol. (2013) 28:1875–9. doi: 10.1007/s00467-013-2485-9
  60. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug safety. (2005) 4, 599–608. doi: 10.1517/14740338.4.3.599
  61. Yelena K, Blanka MK, Vincent RB. Persistent hypogammaglobulinemia after rituximab treatment. J Allergy Clin Immunol. (2013) 196:AB196. doi: 10.1016/j.jaci.2012.12.1366/// Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. (2015) 57:60–5. doi: 10.1016/j.jaut.2014.11.009
  62. Fujinaga S, Ozawa K, Sakuraya K, Yamada A, Shimizu T. Lateonset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome. Clin Nephrol. (2016) 85:340–5. doi: 10.5414/CN108835
  63. Trivin C, Tran A, Moulin B, Choukroun G, Gatault P, Courivaud C, et al. Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney, J. (2017) 10:461–9. doi: 10.1093/ckj/sfw101
  64. Ahn YH, Kang HG, Lee JM, Choi HJ, Ha IS, Cheong HI. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol. (2014) 29:1461–4. doi: 10.1007/s00467-014-2794-7
  65. Kim JH, Park E, Hyun HS, Cho MH, Ahn YH, Choi HJ, et al. Long-term repeated rituximab treatment for childhood steroiddependent nephrotic syndrome. Kid Res Clin Prac. (2017) 36:257–263. doi: 10.23876/j.krcp.2017.36.3.257
  66. Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, et al. (2015). Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 26, 2259–66. doi: 10.1681/ASN.2014080799
  67. Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V, et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol. (2013) 28:911–8. doi: 10.1007/s00467-012-2406-3
  68. Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K. et al. Rituximab for childhood-onset refractory nephrotic syndrome (RCRNS) Study Group Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. (2017) 32:2071–8
  69. Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, et al. Predictors of relapse and long-term outcome in children with steroiddependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol. (2017) 21:671–6. doi: 10.1007/s10157-016-1328-y
  70. Fujinaga S, Sakuraya K. Repeated administrations of rituximab along with steroids and immunosuppressive agents in refractory steroid-resistant. Nephrotic Syndr. (2017) 54:49-50
  71. Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatrics. (2018) 172:757–64. doi: 10.1001/jamapediatrics.2018.1323
  72. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Shorttermeffectsofrituximabinchildrenwithsteroid-andcalcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. (2011) 6:1308–15. doi: 10.2215/CJN.09421010
  73. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. (2014) 384:1273–81. doi: 10.1016/S0140-6736(14)60541-9
  74. Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine. (2018) 97:e13157. doi: 10.1097/MD.0000000000013157
  75. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporinedependent nephrotic syndrome: a multicentric series of 22 cases, Pediatr Nephrol. (2008) 23:1269–79. doi: 10.1007/s00467-008-0814-1
  76. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. (2010) 5:2207–12. doi: 10.2215/CJN.03470410
  77. Webb H, Jaureguiberry G, Dufek S, Tullus K, Bockenhauer D. Cyclophosphamide and rituximab in frequently relapsing/steroiddependent nephrotic syndrome. Pediatric Nephrol. (2016) 31:589–94. doi: 10.1007/s00467-015-3245-9
  78. Niu XL, Hao S, Wang P, Zhang W, Guo GM, Wu Y, et al. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep. (2016) 5:237–242 doi: 10.3892/br.2016.711
  79. Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatr Nephrol. (2015) 30:687–91. doi: 10.1007/s00467-014-3034-x
  80. Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. (2010) 25:1109–15. doi: 10.1007/s00467-010-1465-6
  81. Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, et al. Single infusion of rituximab for persistent steroid-dependent minimalchange nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. (2010) 25:539–44. doi: 10.1007/s00467-009-1377
  82. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.PediatrNephrol.(2009)24:1321–8.doi:10.1007/s00467-009-1191-0
  83. Van Horebeek I, Knops N, Van Dyck M, Levtchenko E, Mekahli D. Rituximab in children with steroid-dependent nephrotic syndrome: experience of a tertiary center and review of the literature. Acta Clin Belg. (2017) 72:147–55. doi: 10.1080/17843286.2016.1208955
  84. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. (2012) 27:1910– 5. doi: 10.1093/ndt/gfr548
  85. Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V, et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol. (2013) 28:911–8. doi: 10.1007/s00467-012-2406-3
  86. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. JASN. (2014) 25:850–63. doi: 10.1681/ASN.2013030251
  87. Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K. et al. Rituximab for childhood-onset refractory nephrotic syndrome (RCRNS) Study Group Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. (2017) 32:2071–8. doi: 10.1007/s00467-017-3718-0

Адрес за кореспонденция:

СБАЛДБ “Проф. Иван Митев” – София, Клиника по детска нефрология и хемодиализа, МУ – София 

Бул., “Акад. Иван Гешов”, 11  

1606, София 

e-mail: galiazlatanova@abv.bg